| [1] |
Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections[J]. J Natl Cancer Inst, 2008, 100(7): 513-517.
|
| [2] |
Gravitt PE. The known unknowns of HPV natural history[J]. J Clin Invest, 2011, 121(12): 4593-4599.
|
| [3] |
Smith JS, Backes DM, Hoots BE, et al. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors[J]. Obstet Gynecol, 2009, 113(4): 917-924.
|
| [4] |
Crum CP, Fu YS, Levine RU, et al. Intraepithelial squamous lesions of the vulva: biologic and histologic criteria for the distinction of condylomas from vulvar intraepithelial neoplasia[J]. Am J Obstet Gynecol, 1982, 144(1): 77-83.
|
| [5] |
Wilkinson EJ, Kneale B, Lynch PJ. Report of the ISSVD terminology committee[J]. J Reprod Med, 1986, 31(12): 973-974.
|
| [6] |
Sideri M, Jones RW, Wilkinson EJ, et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee[J]. J Reprod Med, 2005, 50(11): 807-810.
|
| [7] |
van de Nieuwenhof HP, Massuger LF, van der Avoort IA, et al. Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age[J]. Eur J Cancer, 2009, 45(5): 851-856.
|
| [8] |
Darragh TM, Colgan TJ, Cox JT, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology[J]. J Low Genit Tract Dis, 2012, 16(3): 205-242.
|
| [9] |
Crum CP, Herrington CS, McCluggage WG, et al. Tumours of the vulva; epithelial tumors//Kurman RJ, Carcangiu ML, Herrington CS, et al. eds. WHO classification of tumours of female reproductive organs. 4th ed[M]. Lyon: IARC Press, 2014: 29.
|
| [10] |
Bornstein J, Bogliatto F, Haefner HK, et al. The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) terminology of vulvar squamous intraepithelial lesions[J]. J Low Genit Tract Dis, 2016, 20(1): 11-14.
|
| [11] |
van Seters M, van Beurden M, de Craen AJ. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3 322 published patients[J]. Gynecol Oncol, 2005, 97(2): 645-651.
|
| [12] |
Jones RW, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women[J]. Obstet Gynecol, 2005, 106(6): 1319-1326.
|
| [13] |
Judson PL, Habermann EB, Baxter NN, et al. Trends in the incidence of invasive and in situ vulvar carcinoma[J]. Obstet Gynecol, 2006, 107(5): 1018-1022.
|
| [14] |
de Sanjose S, Alemany L, Ordi J, et al. Worldwide human papillomavirus genotype attribution in over 2 000 cases of intraepithelial and invasive lesions of the vulva[J]. Eur J Cancer, 2013, 49(16): 3450-3461.
|
| [15] |
van Esch EM, Welters MJ, Jordanova ES, et al. Treatment failure in patients with HPV 16-induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy[J]. Expert Rev Vaccines, 2012, 11(7): 821-840.
|
| [16] |
Nelson EL, Stockdale CK. Vulvar and vaginal HPV disease[J]. Obstet Gynecol Clin North Am, 2013, 40(2): 359-376.
|
| [17] |
de Witte CJ, van de Sande AJ, van Beekhuizen HJ, et al. Imiquimod in cervical, vaginal and vulvar intraepithelial neoplasia: a review[J]. Gynecol Oncol, 2015, 139(2): 377-384.
|
| [18] |
van Seters M, van Beurden M, ten Kate FJ, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod[J]. N Engl J Med, 2008, 358(14): 1465-1473.
|
| [19] |
Mathiesen O, Buus SK, Cramers M. Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double-blinded study[J]. Gynecol Oncol, 2007, 107(2): 219-222.
|
| [20] |
Daayana S, Elkord E, Winters U, et al. Phase Ⅱ trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia[J]. Br J Cancer, 2010, 102(7): 1129-1136.
|
| [21] |
Liu XS. Non-responders to topical imiquimod followed by vaccination therapy in VIN patients may be due to the level of IL10[J]. Br J Cancer, 2010, 103(4): 595-596.
|
| [22] |
Ribeiro F, Figueiredo A, Paula T, et al. Vulvar intraepithelial neoplasia: evaluation of treatment modalities[J]. J Low Genit Tract Dis, 2012, 16(3): 313-317.
|
| [23] |
Wallbillich JJ, Rhodes HE, Milbourne AM, et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence[J]. Gynecol Oncol, 2012, 127(2): 312-315.
|
| [24] |
李力. 外阴肿瘤//沈铿， 马丁. 妇产科学. 3版[M]. 北京： 人民卫生出版社， 2016: 302.
|
| [25] |
Saraiya M, Unger ER, Thompson TD, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines[J]. J Natl Cancer Inst, 2015, 107(6): djv086.
|
| [26] |
van der Avoort IA, Shirango H, Hoevenaars BM, et al. Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways[J]. Int J Gynecol Pathol, 2006, 25(1): 22-29.
|
| [27] |
Hoevenaars BM, van der Avoort IA, de Wilde PC, et al. A panel of p16(INK4A), MIB1 and p53 proteins can distinguish between the 2 pathways leading to vulvar squamous cell carcinoma[J]. Int J Cancer, 2008, 123(12): 2767-2773.
|
| [28] |
Ohtani N, Yamakoshi K, Takahashi A, et al. The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression[J]. J Med Invest, 2004, 51(3-4): 146-153.
|
| [29] |
Rufforny I, Wilkinson EJ, Liu C, et al. Human papillomavirus infection and p16(INK4a) protein expression in vulvar intraepithelial neoplasia and invasive squamous cell carcinoma[J]. J Low Genit Tract Dis, 2005, 9(2): 108-113.
|
| [30] |
Santegoets LA, van Baars R, Terlou A, et al. Different DNA damage and cell cycle checkpoint control in low- and high-risk human papillomavirus infections of the vulva[J]. Int J Cancer, 2012, 130(12): 2874-2885.
|
| [31] |
Rakislova N, Saco A, de la Oliva J, et al. Histological characteristics of human papilloma virus-associated and -independent squamous cell carcinomas of the vulva: a study of 1 636 cases[J]. Virchows Archiv, 2016, 469(Suppl 1): S110.
|
| [32] |
Ordi J, Rakislova N, Clavero OOC, et al. Histological characteristics of HPV-associated and -independent squamous cell carcinomas of the vulva: a study of 791 cases[J]. Lab Invest, 2016, 96(Suppl 1s): 300A.
|
| [33] |
Cheng AS, Karnezis AN, Jordan S, et al. p16 immunostaining allows for accurate subclassification of vulvar squamous cell carcinoma into HPV-associated and HPV-independent cases[J]. Int J Gynecol Pathol, 2016, 35(4): 385-393.
|
| [34] |
Watson M, Saraiya M, Wu X. Update of HPV-associated female genital cancers in the United States, 1999-2004[J]. J Womens Health (Larchmt), 2009, 18(11): 1731-1738.
|
| [35] |
Gunderson CC, Nugent EK, Elfrink SH, et al. A contemporary analysis of epidemiology and management of vaginal intraepithelial neoplasia[J]. Am J Obstet Gynecol, 2013, 208(5): 410. e1-e6.
|
| [36] |
Sillman FH, Fruchter RG, Chen YS, et al. Vaginal intraepithelial neoplasia: risk factors for persistence, recurrence, and invasion and its management[J]. Am J Obstet Gynecol, 1997, 176(1 Pt 1): 93-99.
|
| [37] |
Aho M, Vesterinen E, Meyer B, et al. Natural history of vaginal intraepithelial neoplasia[J]. Cancer, 1991, 68(1): 195-197.
|
| [38] |
Gemmell J, Holmes DM, Duncan ID. How frequently need vaginal smears be taken after hysterectomy for cervical intraepithelial neoplasia？[J]. Br J Obstet Gynaecol, 1990, 97(1): 58-61.
|
| [39] |
Schockaert S, Poppe W, Arbyn M, et al. Incidence of vaginal intraepithelial neoplasia after hysterectomy for cervical intraepithelial neoplasia: a retrospective study[J]. Am J Obstet Gynecol, 2008, 199(2): 113. e1-e5.
|
| [40] |
Koo YJ, Min KJ, Hong JH, et al. Efficacy of poly-gamma-glutamic acid in women with high-risk human papillomavirus-positive vaginal intraepithelial neoplasia: an observational pilot study[J]. J Microbiol Biotechnol, 2015, 25(7): 1163-1169.
|
| [41] |
Caglar H, Hertzog RW, Hreshchyshyn MM. Topical 5-fluorouracil treatment of vaginal intraepithelial neoplasia[J]. Obstet Gynecol, 1981, 58(5): 580-583.
|
| [42] |
Kirwan P, Naftalin NJ. Topical 5-fluorouracil in the treatment of vaginal intraepithelial neoplasia[J]. Br J Obstet Gynaecol, 1985, 92(3): 287-291.
|
| [43] |
Gurumurthy M, Cruickshank ME. Management of vaginal intraepithelial neoplasia[J]. J Low Genit Tract Dis, 2012, 16(3): 306-312.
|
| [44] |
Hellman K, Silfverswärd C, Nilsson B, et al. Primary carcinoma of the vagina: factors influencing the age at diagnosis. The radiumhemmet series 1956-96[J]. Int J Gynecol Cancer, 2004, 14(3): 491-501.
|
| [45] |
Ratnavelu N, Patel A, Fisher AD, et al. High-grade vaginal intraepithelial neoplasia: can we be selective about who we treat？[J]. BJOG, 2013, 120(7): 887-893.
|
| [46] |
Liao JB, Jean S, Wilkinson-Ryan I, et al. Vaginal intraepithelial neoplasia (VAIN) after radiation therapy for gynecologic malignancies: a clinically recalcitrant entity[J]. Gynecol Oncol, 2011, 120(1): 108-112.
|
| [47] |
Rajaram S, Maheshwari A, Srivastava A. Staging for vaginal cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2015, 29(6): 822-832.
|
| [48] |
Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase Ⅲ trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine[J]. J Infect Dis, 2009, 199(6): 805-814.
|
| [49] |
薛凤霞， 刘宏图， 刘朝晖，等. 女性下生殖道人乳头瘤病毒感染诊治专家共识[J]. 中国实用妇科与产科杂志， 2015, 31(10): 894-897.
|
| [50] |
Pitisuttithum P, Velicer C, Luxembourg A. 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV[J]. Exp Rev Vaccines, 2015, 14(11): 1405-1419.
|
| [51] |
Serrano B, de Sanjose S, Tous S, et al. Human papillomavirus genotype attribution for HPV-6, -11, -16, -18, -31, -33, -45, -52 and -58 in female anogenital lesions[J]. Eur J Cancer, 2015, 51(13): 1732-1741.
|
| [52] |
Alemany L, Saunier M, Tinoco L, et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples[J]. Eur J Cancer, 2014, 50(16): 2846-2854.
|